AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Quantum Biopharma shares rise 1.49% premarket after Adaptimmune's deal with US WorldMeds.
ByAinvest
Tuesday, Jul 29, 2025 7:23 am ET1min read
Quantum Biopharma Ltd. rose 1.49% in premarket trading, with Adaptimmune's announcement of a definitive agreement with US WorldMeds to bring lete-cel to market and continue development of uza-cel in collaboration with Galapagos. The transaction includes a $55 million cash payment and up to $30 million in potential future payments upon achieving certain milestones. Adaptimmune will retain rights to its preclinical assets and restructure to support the transition of these therapies to US WorldMeds. Additionally, Sanofi's Sarclisa received approval in the EU for the treatment of newly diagnosed multiple myeloma, which may positively impact the biopharma sector.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet